Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015 Nov 23;60(2):855-61.
doi: 10.1128/AAC.01913-15. Print 2016 Feb.

Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir

Jennifer R King  1 , Sandeep Dutta  2 , Daniel Cohen  3 , Thomas J Podsadecki  3 , Bifeng Ding  4 , Walid M Awni  2 , Rajeev M Menon  2
Affiliations
Clinical Trial

Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir

Jennifer R King et al. Antimicrob Agents Chemother. .

Abstract

The combination of ombitasvir (an NS5A inhibitor), paritaprevir (an NS3/4A inhibitor) coadministered with ritonavir (r), and dasabuvir (an NS5B nonnucleoside polymerase inhibitor), referred to as the 3D regimen, and the combination of ombitasvir-paritaprevir-r, referred to as the 2D regimen, have demonstrated high efficacy with and without ribavirin in hepatitis C virus (HCV)-infected subjects. These regimens have potential for coadministration with sofosbuvir (nucleoside NS5B inhibitor) in the treatment of HCV. This phase 1, drug-drug interaction, open-label, multiple-dose study enrolled 32 healthy subjects to receive the 3D or 2D regimen in combination with sofosbuvir. Doses of study drugs were as follows: ombitasvir-paritaprevir-r, 25/150/100 mg daily (QD); dasabuvir, 250 mg twice daily (BID); and sofosbuvir, 400 mg QD. Blood samples were collected on study days 7, 14, and 21 for evaluating drug interaction at steady state. The effect of the 3D and 2D regimens on the pharmacokinetics of sofosbuvir and its circulating metabolite GS-331007 and vice versa was assessed by a repeated-measures analysis. Exposures of the 3D and 2D regimens were similar (≤20% change) during coadministration with sofosbuvir and during administration alone. Sofosbuvir exposures were 61% to 112% higher with the 3D regimen and 64% to 93% higher with the 2D regimen than with sofosbuvir alone. GS-331007 total exposures were 27% and 32% higher with the 3D and 2D regimens, respectively, than with sofosbuvir alone. Increases in sofosbuvir and GS-331007 exposures likely resulted from breast cancer resistance protein (BCRP) and/or P glycoprotein (P-gp) transporter inhibition by paritaprevir and ritonavir. No subjects discontinued the study due to study drug-related adverse events. No dose adjustment is recommended for 3D, 2D, or sofosbuvir in clinical trials exploring the safety and efficacy of the combination. (This study has been registered at ClinicalTrials.gov under registration no. NCT02356562 and NCT02292719.).

PubMed Disclaimer

Figures

FIG 1
FIG 1
Study design for the 3D arm (arm 1) and the 2D arm (arm 2).
FIG 2
FIG 2
Mean plasma concentration-time profiles of sofosbuvir and GS-331007 with (day 21) and without (day 7) the 3D (arm 1) and 2D (arm 2) regimen.
See this image and copyright information in PMC

References

    1. AbbVie Inc. 2014. Viekira Pak package insert. AbbVie Inc., North Chicago, IL.
    1. AbbVie Inc. 2014. Viekirax summary of product characteristics. AbbVie Inc., Maidenhead, United Kingdom.
    1. Lawitz E, Hezode C, Varunok P, Thuluvath PJ, Baykal T, Kapoor M, Lovell SS, Wang T, Pilot-Matias T, Vilchez R, Bernstein B. 2013. Interferon- and ribavirin-free regimen of ABT-450/r + ABT-267 in HCV genotype 1b-infected treatment-naïve patients and prior null responders. Hepatology 58(Suppl):244A.
    1. Hézode C, Asselah T, Reddy RK, Hassanein T, Berenguer M, Fleischer-Stepniewska K, Marcellin P, Hall C, Schnell G, Pilot-Matias T, Mobashery N, Redman R, Vilchez RA, Pol S. 2015. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet 385:2502–2509. doi: 10.1016/S0140-6736(15)60159-3. - DOI - PubMed
    1. Lawitz E, Sullivan G, Rodriguez-Torres M, Bennett M, Poordad F, Kapoor M, Badri P, Campbell A, Rodigues L, Hu Y, Pilot-Matias T, Vilchez RA. 2015. Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection. J Infect 70:197–205. doi: 10.1016/j.jinf.2014.09.008. - DOI - PubMed

Publication types

MeSH terms

Associated data